-
Joining Forces for Pathology Diagnostics with AI Assistance: The EMPAIA Initiative
Authors:
Norman Zerbe,
Lars Ole Schwen,
Christian Geißler,
Katja Wiesemann,
Tom Bisson,
Peter Boor,
Rita Carvalho,
Michael Franz,
Christoph Jansen,
Tim-Rasmus Kiehl,
Björn Lindequist,
Nora Charlotte Pohlan,
Sarah Schmell,
Klaus Strohmenger,
Falk Zakrzewski,
Markus Plass,
Michael Takla,
Tobias Küster,
André Homeyer,
Peter Hufnagl
Abstract:
Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces. The open and vendor-neutral EMPAIA initiative addresses…
▽ More
Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces. The open and vendor-neutral EMPAIA initiative addresses these challenges. Here, we provide an overview of EMPAIA's achievements and lessons learned. EMPAIA integrates various stakeholders of the pathology AI ecosystem, i.e., pathologists, computer scientists, and industry. In close collaboration, we developed technical interoperability standards, recommendations for AI testing and product development, and explainability methods. We implemented the modular and open-source EMPAIA platform and successfully integrated 14 AI-based image analysis apps from 8 different vendors, demonstrating how different apps can use a single standardized interface. We prioritized requirements and evaluated the use of AI in real clinical settings with 14 different pathology laboratories in Europe and Asia. In addition to technical developments, we created a forum for all stakeholders to share information and experiences on digital pathology and AI. Commercial, clinical, and academic stakeholders can now adopt EMPAIA's common open-source interfaces, providing a unique opportunity for large-scale standardization and streamlining of processes. Further efforts are needed to effectively and broadly establish AI assistance in routine laboratory use. To this end, a sustainable infrastructure, the non-profit association EMPAIA International, has been established to continue standardization and support broad implementation and advocacy for an AI-assisted digital pathology future.
△ Less
Submitted 16 April, 2024; v1 submitted 22 December, 2023;
originally announced January 2024.
-
Recommendations on test datasets for evaluating AI solutions in pathology
Authors:
André Homeyer,
Christian Geißler,
Lars Ole Schwen,
Falk Zakrzewski,
Theodore Evans,
Klaus Strohmenger,
Max Westphal,
Roman David Bülow,
Michaela Kargl,
Aray Karjauv,
Isidre Munné-Bertran,
Carl Orge Retzlaff,
Adrià Romero-López,
Tomasz Sołtysiński,
Markus Plass,
Rita Carvalho,
Peter Steinbach,
Yu-Chia Lan,
Nassim Bouteldja,
David Haber,
Mateo Rojas-Carulla,
Alireza Vafaei Sadr,
Matthias Kraft,
Daniel Krüger,
Rutger Fick
, et al. (5 additional authors not shown)
Abstract:
Artificial intelligence (AI) solutions that automatically extract information from digital histology images have shown great promise for improving pathological diagnosis. Prior to routine use, it is important to evaluate their predictive performance and obtain regulatory approval. This assessment requires appropriate test datasets. However, compiling such datasets is challenging and specific recom…
▽ More
Artificial intelligence (AI) solutions that automatically extract information from digital histology images have shown great promise for improving pathological diagnosis. Prior to routine use, it is important to evaluate their predictive performance and obtain regulatory approval. This assessment requires appropriate test datasets. However, compiling such datasets is challenging and specific recommendations are missing.
A committee of various stakeholders, including commercial AI developers, pathologists, and researchers, discussed key aspects and conducted extensive literature reviews on test datasets in pathology. Here, we summarize the results and derive general recommendations for the collection of test datasets.
We address several questions: Which and how many images are needed? How to deal with low-prevalence subsets? How can potential bias be detected? How should datasets be reported? What are the regulatory requirements in different countries?
The recommendations are intended to help AI developers demonstrate the utility of their products and to help regulatory agencies and end users verify reported performance measures. Further research is needed to formulate criteria for sufficiently representative test datasets so that AI solutions can operate with less user intervention and better support diagnostic workflows in the future.
△ Less
Submitted 21 April, 2022;
originally announced April 2022.
-
Predicting Prostate Cancer-Specific Mortality with A.I.-based Gleason Grading
Authors:
Ellery Wulczyn,
Kunal Nagpal,
Matthew Symonds,
Melissa Moran,
Markus Plass,
Robert Reihs,
Farah Nader,
Fraser Tan,
Yuannan Cai,
Trissia Brown,
Isabelle Flament-Auvigne,
Mahul B. Amin,
Martin C. Stumpe,
Heimo Muller,
Peter Regitnig,
Andreas Holzinger,
Greg S. Corrado,
Lily H. Peng,
Po-Hsuan Cameron Chen,
David F. Steiner,
Kurt Zatloukal,
Yun Liu,
Craig H. Mermel
Abstract:
Gleason grading of prostate cancer is an important prognostic factor but suffers from poor reproducibility, particularly among non-subspecialist pathologists. Although artificial intelligence (A.I.) tools have demonstrated Gleason grading on-par with expert pathologists, it remains an open question whether A.I. grading translates to better prognostication. In this study, we developed a system to p…
▽ More
Gleason grading of prostate cancer is an important prognostic factor but suffers from poor reproducibility, particularly among non-subspecialist pathologists. Although artificial intelligence (A.I.) tools have demonstrated Gleason grading on-par with expert pathologists, it remains an open question whether A.I. grading translates to better prognostication. In this study, we developed a system to predict prostate-cancer specific mortality via A.I.-based Gleason grading and subsequently evaluated its ability to risk-stratify patients on an independent retrospective cohort of 2,807 prostatectomy cases from a single European center with 5-25 years of follow-up (median: 13, interquartile range 9-17). The A.I.'s risk scores produced a C-index of 0.84 (95%CI 0.80-0.87) for prostate cancer-specific mortality. Upon discretizing these risk scores into risk groups analogous to pathologist Grade Groups (GG), the A.I. had a C-index of 0.82 (95%CI 0.78-0.85). On the subset of cases with a GG in the original pathology report (n=1,517), the A.I.'s C-indices were 0.87 and 0.85 for continuous and discrete grading, respectively, compared to 0.79 (95%CI 0.71-0.86) for GG obtained from the reports. These represent improvements of 0.08 (95%CI 0.01-0.15) and 0.07 (95%CI 0.00-0.14) respectively. Our results suggest that A.I.-based Gleason grading can lead to effective risk-stratification and warrants further evaluation for improving disease management.
△ Less
Submitted 24 November, 2020;
originally announced December 2020.
-
Interpretable Survival Prediction for Colorectal Cancer using Deep Learning
Authors:
Ellery Wulczyn,
David F. Steiner,
Melissa Moran,
Markus Plass,
Robert Reihs,
Fraser Tan,
Isabelle Flament-Auvigne,
Trissia Brown,
Peter Regitnig,
Po-Hsuan Cameron Chen,
Narayan Hegde,
Apaar Sadhwani,
Robert MacDonald,
Benny Ayalew,
Greg S. Corrado,
Lily H. Peng,
Daniel Tse,
Heimo Müller,
Zhaoyang Xu,
Yun Liu,
Martin C. Stumpe,
Kurt Zatloukal,
Craig H. Mermel
Abstract:
Deriving interpretable prognostic features from deep-learning-based prognostic histopathology models remains a challenge. In this study, we developed a deep learning system (DLS) for predicting disease specific survival for stage II and III colorectal cancer using 3,652 cases (27,300 slides). When evaluated on two validation datasets containing 1,239 cases (9,340 slides) and 738 cases (7,140 slide…
▽ More
Deriving interpretable prognostic features from deep-learning-based prognostic histopathology models remains a challenge. In this study, we developed a deep learning system (DLS) for predicting disease specific survival for stage II and III colorectal cancer using 3,652 cases (27,300 slides). When evaluated on two validation datasets containing 1,239 cases (9,340 slides) and 738 cases (7,140 slides) respectively, the DLS achieved a 5-year disease-specific survival AUC of 0.70 (95%CI 0.66-0.73) and 0.69 (95%CI 0.64-0.72), and added significant predictive value to a set of 9 clinicopathologic features. To interpret the DLS, we explored the ability of different human-interpretable features to explain the variance in DLS scores. We observed that clinicopathologic features such as T-category, N-category, and grade explained a small fraction of the variance in DLS scores (R2=18% in both validation sets). Next, we generated human-interpretable histologic features by clustering embeddings from a deep-learning based image-similarity model and showed that they explain the majority of the variance (R2 of 73% to 80%). Furthermore, the clustering-derived feature most strongly associated with high DLS scores was also highly prognostic in isolation. With a distinct visual appearance (poorly differentiated tumor cell clusters adjacent to adipose tissue), this feature was identified by annotators with 87.0-95.5% accuracy. Our approach can be used to explain predictions from a prognostic deep learning model and uncover potentially-novel prognostic features that can be reliably identified by people for future validation studies.
△ Less
Submitted 17 November, 2020;
originally announced November 2020.
-
A glass-box interactive machine learning approach for solving NP-hard problems with the human-in-the-loop
Authors:
Andreas Holzinger,
Markus Plass,
Katharina Holzinger,
Gloria Cerasela Crisan,
Camelia-M. Pintea,
Vasile Palade
Abstract:
The goal of Machine Learning to automatically learn from data, extract knowledge and to make decisions without any human intervention. Such automatic (aML) approaches show impressive success. Recent results even demonstrate intriguingly that deep learning applied for automatic classification of skin lesions is on par with the performance of dermatologists, yet outperforms the average. As human per…
▽ More
The goal of Machine Learning to automatically learn from data, extract knowledge and to make decisions without any human intervention. Such automatic (aML) approaches show impressive success. Recent results even demonstrate intriguingly that deep learning applied for automatic classification of skin lesions is on par with the performance of dermatologists, yet outperforms the average. As human perception is inherently limited, such approaches can discover patterns, e.g. that two objects are similar, in arbitrarily high-dimensional spaces what no human is able to do. Humans can deal only with limited amounts of data, whilst big data is beneficial for aML; however, in health informatics, we are often confronted with a small number of data sets, where aML suffer of insufficient training samples and many problems are computationally hard. Here, interactive machine learning (iML) may be of help, where a human-in-the-loop contributes to reduce the complexity of NP-hard problems. A further motivation for iML is that standard black-box approaches lack transparency, hence do not foster trust and acceptance of ML among end-users. Rising legal and privacy aspects, e.g. with the new European General Data Protection Regulations, make black-box approaches difficult to use, because they often are not able to explain why a decision has been made. In this paper, we present some experiments to demonstrate the effectiveness of the human-in-the-loop approach, particularly in opening the black-box to a glass-box and thus enabling a human directly to interact with an learning algorithm. We selected the Ant Colony Optimization framework, and applied it on the Traveling Salesman Problem, which is a good example, due to its relevance for health informatics, e.g. for the study of protein folding. From studies of how humans extract so much from so little data, fundamental ML-research also may benefit.
△ Less
Submitted 3 August, 2017;
originally announced August 2017.
-
Approaches to link RNA secondary structures with splicing regulation
Authors:
Mireya Plass,
Eduardo Eyras
Abstract:
In higher eukaryotes, alternative splicing is usually regulated by protein factors, which bind to the pre-mRNA and affect the recognition of splicing signals. There is recent evidence that the secondary structure of the pre-mRNA may also play an important role in this process, either by facilitating or by hindering the interaction with factors and small nuclear ribonucleoproteins (snRNPs) that reg…
▽ More
In higher eukaryotes, alternative splicing is usually regulated by protein factors, which bind to the pre-mRNA and affect the recognition of splicing signals. There is recent evidence that the secondary structure of the pre-mRNA may also play an important role in this process, either by facilitating or by hindering the interaction with factors and small nuclear ribonucleoproteins (snRNPs) that regulate splicing. Moreover, the secondary structure could play a fundamental role in the splicing of yeast species, which lack many of the regulatory splicing factors present in metazoans. This review describes the steps in the analysis of the secondary structure of the pre-mRNA and its possible relation to splicing. As a working example, we use the case of yeast and the problem of the recognition of the 3-prime splice site.
△ Less
Submitted 9 October, 2015;
originally announced October 2015.
